Molecular-targeted approaches to reduce renal accumulation of nephrotoxic drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 9, 2010, Pages 1125-1138

  Nagai, Junya ^a   Takano, Mikihisa ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Aminoglycoside antibiotics; Competition based targeting; Drug induced nephrotoxicity; Megalin; Radiolabeled somatostatin analogs; Receptor mediated endocytosis

Indexed keywords

ACTIN; AMIKACIN; AMINO ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; APROTININ; ASPARAGINYLPROLYLLYSYLLYSYLTYROSYLISOLEUCYLPROLYLGLYCYLTHREONYLLYSYLMETHIONYLISOLEUCYLPHENYLALANYLALANYLGLYCYLISOLEUCYLLYSYLLYSYLLYSYLGLYCINE; CUBILIN; CYTOCHROME C; GELSOLIN; GENTAMICIN; HABEKACIN; KANAMYCIN; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; LYSOZYME; LYSYLGLYCYLGLYCYLLYSYLHISTIDYLLYSYLTHREONYLGLYCYLPROLYLASPARAGINYLLEUCYLHISTIDYLGLYCYLLEUCYLPHENYLALANYLGLYCYLARGINYLLYSYLTHREONYLGLYCINE; LYSYLHISTIDYLVALYLVALYLPROLYLASPARAGINYLGLUTAMYLVALYLVALYLVALYLGLUTAMINYLARGINYLLEUCYLPHENYLALANYLGLUTAMINYLVALYLLYSYLGLYCYLARGINYLARGININE; LYSYLLYSYLLEUCYLTYROSYLGLUTAMINYLVALYLLYSYLGLYCYLLYSYLLYSINE; LYSYLMETHIONYLISOLEUCYLPHENYLALANYLALANYLGLYCYLISOLEUCYLLYSYLLYSYLLYSINE; MEGALIN; NEOMYCIN; NETILMICIN; NEURAL WISKOTT ALDRICH SYNDROME PROTEIN; OCTREOTIDE; PEPTIDE FRAGMENT; SOMATOSTATIN DERIVATIVE; STREPTOMYCIN; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SUBSTITUTION; DRUG ACCUMULATION; DRUG BINDING; DRUG INHIBITION; DRUG MECHANISM; DRUG UPTAKE; ENDOCYTOSIS; GLOMERULUS FILTRATION; HUMAN; KIDNEY CELL; KIDNEY TUBULE CELL; KIDNEY TUMOR; MENINGITIS; MOLECULAR THERAPY; NEPHROTOXICITY; NEWBORN SEPSIS; NONHUMAN; RECEPTOR BINDING; REVIEW; URINARY TRACT INFECTION;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; KIDNEY; KIDNEY TUBULES, PROXIMAL; LDL-RECEPTOR RELATED PROTEIN 2; LIGANDS; MICE; MICE, KNOCKOUT; PEPTIDES; PHARMACEUTICAL PREPARATIONS; RATS; SOMATOSTATIN;

EID: 77955776508     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.497140     Document Type: Review

References (106)

1. Nolin TD, Himmelfarb J. Mechanisms of drug-induced nephrotoxicity. Handb Exp Pharmacol 2010;(196):111-130
2. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med 2008;36(Suppl 4):S216-23
3. Inui K, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 2000;58(3):944-958
4. Tune BM. Nephrotoxicity of beta-lactam antibiotics: mechanisms and strategies for prevention. Pediatr Nephrol 1997;11(6):768-772
5. Kropp H, Sundelof JG, Hajdu R, Kahan FM. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother 1982;22(1):62-70
6. Kahan FM, Kropp H, Sundelof JG, Birnbaum J. Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother 1983;12(Suppl D):1-35
7. Birnbaum J, Kahan FM, Kropp H, MacDonald JS. Carbapenems, a new class of beta-lactam antibiotics. Discovery and improvement of imipenem/cilastatin. Am J Med 1985;78(Suppl 6A):3-21
8. Hirouchi Y, Naganuma H, Kawahara Y, et al. Protective effect of N-acyl amino acids (NAAs) on cephaloridine (CER) nephrotoxicity in rabbits. Jpn J Pharmacol 1993;63(4):487-493
9. Hirouchi Y, Naganuma H, Kawahara Y, et al. Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex. Jpn J Pharmacol 1994;66(1):1-6
10. Wright EM. Renal Na+-glucose cotransporters. Am J Physiol Renal Physiol 2001;280(1):F10-8
11. Verrey F, Singer D, Ramadan T, et al. Kidney amino acid transport. Pflugers Arch 2009;458(1):53-60
12. Maack T. Renal handling of low molecular weight proteins. Am J Med 1975;58(1):57-64
13. Christensen EI, Birn H, Verroust P, Moestrup SK. Membrane receptors for endocytosis in the renal proximal tubule. Int Rev Cytol 1998;180:237-284 (Pubitemid 28122166)
14. Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci USA 1982;79(18):5557-5561
15. Saito A, Pietromonaco S, Loo AK, Farquhar MG. Complete cloning and sequencing of rat gp330/"megalin," a distinctive member of the low density lipoprotein receptor gene family. Proc Natl Acad Sci USA 1994;91(21):9725-9729
16. Moestrup SK, Kozyraki R, Kristiansen M, et al. The intrinsic factor-vitamin B12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins. J Biol Chem 1998;273(9):5235-5242
17. Christensen EI, Birn H. Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 2002;3(4):256-266
18. Christensen EI, Gburek J. Protein reabsorption in renal proximal tubule-function and dysfunction in kidney pathophysiology. Pediatr Nephrol 2004;19(7):714-721
19. Moestrup SK, Kozyraki R. Cubilin, a high-density lipoprotein receptor. Curr Opin Lipidol 2000;11(2):133-140
20. Christensen EI, Verroust PJ, Nielsen R. Receptor-mediated endocytosis in renal proximal tubule. Pflugers Arch 2009,458(6): 1039-1048
21. Moestrup SK, Cui S, Vorum H, et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995, 96(3): 1404-1413
22. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999;43(5):1003-1012
23. Nagai J, Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokin 2004;19(3):159-170
24. Tauris J, Christensen EI, Nykjaer A, et al. Cubilin and megalin co-localize in the neonatal inner ear. Audiol Neurotol 2009;14(4):267-278
25. Rolleman EJ, Melis M, Valkema R, et al. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010;37(5):1018-1031
26. de Jong M, Barone R, Krenning E, et al. Megalin is essential for renal proximal tubule reabsorption of 111In-DTPA-octreotide. J Nucl Med 2005;46(10):1696-1700
27. Chambers HF. The aminoglycosides. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 10th edition. McGraw-Hill, New York; 2001. p. 1219-1238
28. Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988;33(4):900-911
29. Molitoris BA. Cell biology of aminoglycoside nephrotoxicity: newer aspects. Curr Opin Nephrol Hypertens 1997;6(4):384-388
30. El Mouedden M, Laurent G, Mingeot-Leclercq MP, Tulkens PM. Gentamicin-induced apoptosis in renal cell lines and embryonic rat fibroblasts. Toxicol Sci 2000;56(1):229-239
31. Vandewalle A, Farman N, Morin JP, et al. Gentamicin incorporation along the nephron: autoradiographic study on isolated tubules. Kidney Int 1981;19(4):529-539 (Pubitemid 11120899)
32. Wedeen RP, Batuman V, Cheeks C, et al. Transport of gentamicin in rat proximal tubule. Lab Invest 1983;48(2):212-223
33. Silverblatt FJ, Kuehn C. Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int 1979;15:335-345
34. Saito H, Inui K, Hori R. Mechanisms of gentamicin transport in kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1986;238(3):1071-1076
35. Inui K, Saito H, Iwata T, Hori R. Aminoglycoside-induced alterations in apical membranes of kidney epithelial cell line (LLC-PK1). Am J Physiol 1988;254(2 Pt 1):C251-7
36. Hori R, Okuda M, Ohishi Y. et al. Surface binding and intracellular uptake of gentamicin in the cultured kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1992;261(3):1200-1205
37. Takano M, Ohishi Y, Okuda M, et al. Transport of gentamicin and fluid-phase endocytosis markers in the LLC-PK1 kidney epithelial cell line. J Pharmacol Exp Ther 1994;268(2):669-674
38. Sandoval R, Leiser J, Molitoris BA. Aminoglycoside antibiotics traffic to the Golgi complex in LLC-PK1 cells. J Am Soc Nephrol 1998;9(2):167-174
39. Schacht J. Isolation of an aminoglycoside receptor from guinea pig inner ear tissues and kidney. Arch Otorhinolaryngol 1979;224(1-2):129-134
40. Sastrasinh M, Knauss TC, Weinberg JM, Humes HD. Identification of the aminoglycoside binding site in rat renal brush border membranes. J Pharmacol Exp Ther 1982;222(2):350-358
41. Molitoris BA, Meyer C, Dahl R, Geerdes A. Mechanism of ischemia-enhanced aminoglycoside binding and uptake by proximal tubule cells. Am J Physiol 1993;264(5 Pt 2):F907-16
42. Christensen EI, Nielsen S, Moestrup SK, et al. Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. Eur J Cell Biol 1995;66(4):349-364
43. Nagai J, Tanaka H, Nakanishi N, et al. Role of megalin in renal handling of aminoglycosides. Am J Physiol Renal Physiol 2001;281(2):F337-44
44. Bergeron M, Mayers P, Brown D. Specific effect of maleate on an apical membrane glycoprotein (gp330) in proximal tubule of rat kidneys. Am J Physiol 1996;271(4 Pt 2):F908-16
45. Schmitz C, Hilpert J, Jacobsen C, et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem 2002;277(1):618-22
46. Ward DT, McLarnon SJ, Riccardi D. Aminoglycosides increase intracellular calcium levels and ERK activity in proximal tubular OK cells expressing the extracellular calcium-sensing receptor. J Am Soc Nephrol 2002;13(6):1481-1489
47. Ward DT, Maldonado-Perez D, Hollins L, Riccardi D. Aminoglycosides induce acute cell signaling and chronic cell death in renal cells that express the calcium-sensing receptor. J Am Soc Nephrol 2005;16(5):1236-1244
48. Gibbons CE, Maldonado-Perez D, Shah AN, et al. Calcium-sensing receptor antagonism or lithium treatment ameliorates aminoglycoside-induced cell death in renal epithelial cells. Biochim Biophys Acta 2008;1782(3):188-195
49. Kounnas MZ, Argraves WS, Strickland DK. The 39-kDa receptor-associated protein interacts with two members of the low density lipoprotein receptor family, alpha 2-macroglobulin receptor and glycoprotein 330. J Biol Chem 1992;267(29):21162-21166
50. Orlando RA, Kerjaschki D, Kurihara H, et al. gp330 associates with a 44-kDa protein in the rat kidney to form the Heymann nephritis antigenic complex. Proc Natl Acad Sci USA 1992;89(15):6698-6702
51. Birn H, Verroust PJ, Nexo E, et al. Characterization of an epithelial approximately 460-kDa protein that facilitates endocytosis of intrinsic factor-vitamin B12 and binds receptor-associated protein. J Biol Chem 1997;272(42):26497-26504
52. Kristiansen M, Kozyraki R, Jacobsen C, et al. Molecular dissection of the intrinsic factor-vitamin B12 receptor, cubilin, discloses regions important for membrane association and ligand binding. J Biol Chem 1999;274(29):20540-20544
53. Orlando RA, Rader K, Authier F, et al. Megalin is an endocytic receptor for insulin. J Am Soc Nephrol 1998;9(10):1759-1766
54. Nagai J, Katsube T, Murakami T, Takano M. Effect of gentamicin on pharmacokinetics of lysozyme in rats: interaction between megalin substrates in the kidney. J Pharm Pharmacol 2002;54(11):1491-1496
55. Watanabe A, Nagai J, Adachi Y, et al. Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor antagonists. J Control Release 2004;95(3):423-433
56. Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 1994;63:601-637
57. Zhai XY, Nielsen R, Birn H, et al. Cubilin- and megalin-mediated uptake of albumin in cultured proximal tubule cells of opossum kidney. Kidney Int 2000;58(4):1523-1533
58. Yu FX, Johnston PA, Sudhof TC, Yin HL. gCap39, a calcium ion- and polyphosphoinositide-regulated actin capping protein. Science 1990;250(4986):1413-1415
59. Janmey PA, Lamb J, Allen PG, Matsudaira PT. Phosphoinositide-binding peptides derived from the sequences of gelsolin and villin. J Biol Chem 1992;267(17):11818-11823
60. Prehoda KE, Scott JA, Mullins RD, Lim WA. Integration of multiple signals through cooperative regulation of the N-WASP-Arp2/3 complex. Science 2000;290(5492):801-806
61. Nagai J, Saito M, Adachi Y, et al. Inhibition of gentamicin binding to rat renal brush-border membrane by megalin ligands and basic peptides. J Control Release 2006;112(1):43-50
62. Hong SY, Oh JE, Lee KH. Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem Pharmacol 1999;58(11):1775-1780
63. Hamamoto K, Kida Y, Zhang Y, et al. Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. Microbiol Immunol 2002;46(11):741-749
64. Tugyi R, Uray K, Ivan D, et al. Partial D-amino acid substitution: improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc Natl Acad Sci USA 2005;102(2):413-418
65. Murakami S, Nagai J, Fujii K, et al. Influences of dosage regimen and co-administration of low-molecular weight proteins and basic peptides on renal accumulation of arbekacin in mice. J Antimicrob Chemother 2008;61(3):658-664
66. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003;55(10):1261-1277
67. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10(21):1451-1458
68. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009;6(1):1-16
69. Fujii K, Nagai J, Sawada T, et al. Effect of PEGylation of N-WASP181-200 on the inhibitory potency for renal aminoglycoside accumulation. Bioconjug Chem 2009;20(8):1553-1558
70. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly (ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994;83(4):601-606
71. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001;12(2):195-202
72. Jedrzejewski K, Kugler P. Peptidases in the kidney and urine of rats after castration. Histochemistry 1982;74(1):63-84
73. Kugler P, Wolf G, Scherberich J. Histochemical demonstration of peptidases in the human kidney. Histochemistry 1985;83(4):337-341
74. Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D- Phe1]-octreotide. A case history. Ann NY Acad Sci 1994;733:496-506
75. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26(11):1439-1447
76. Mezo G, Manea M. Receptor-mediated tumor targeting based on peptide hormones. Expert Opin Drug Deliv 2010;7(1):79-96
77. De Jong M, Valkema R, Van Gameren A, et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [111In-DTPA] octreotide. J Nucl Med 2004;45(7):1168-1171
78. Melis M, Krenning EP, Bernard BF, et al. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging 2005;32(10):1136-1143
79. Barone R, Van Der Smissen P, Devuyst O, et al. Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line. Kidney Int 2005;67(3):969-976
80. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111- diethylenetriaminepentaacetic acid-octreo- tide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 1997;57(4):659-671
81. Mogensen CE, Solling K. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977;37(6):477-486
82. Hammond PJ, Wade AF, Gwilliam ME, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993;67(6):1437-1439
83. de Jong M, Rolleman EJ, Bernard BF, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37(8):1388-1392
84. Bernard BF, Krenning EP, Breeman WA, et al. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38(12):1929-1933
85. Thelle K, Christensen EI, Vorum H, et al. Characterization of proteinuria and tubular protein uptake in a new model of oral L-lysine administration in rats. Kidney Int 2006;69(8):1333-1340
86. ten Dam MA, Branten AJ, Klasen IS, Wetzels JF. The gelatin-derived plasma substitute Gelofusine causes low-molecular-weight proteinuria by decreasing tubular protein reabsorption. J Crit Care 2001;16(3):115-120
87. Veldman BA, Schepkens HL, Vervoort G, et al. Low concentrations of intravenous polygelines promote low-molecular weight proteinuria. Eur J Clin Invest 2003;33(11):962-968
88. van Eerd JE, Vegt E, Wetzels JF, et al. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med 2006;47(3):528-533
89. Melis M, Bijster M, de Visser M, et al. Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours. Eur J Nucl Med Mol Imaging 2009;36(12):1968-1976
90. Gotthardt M, van Eerd-Vismale J, Oyen WJ, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007;48(4):596-601
91. Cui S, Verroust PJ, Moestrup SK, Christensen EI. Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol 1996;271(4 Pt 2):F900-7
92. Birn H, Fyfe JC, Jacobsen C, et al. Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J Clin Invest 2000;105(10):1353-1361
93. Vegt E, van Eerd JE, Eek A, et al. Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med 2008;49(9):1506-1511
94. Christensen EI, Birn H, Rippe B, Maunsbach AB. Controversies in nephrology: renal albumin handling, facts, and artifacts! Kidney Int 2007;72(10):1192-1194
95. Vegt E, Eek A, Oyen WJ, et al. Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. Eur J Nucl Med Mol Imaging 2010;37(2):226-234
96. Pimm MV, Gribben SJ. Prevention of renal tubule re-absorption of radiometal (indium-111) labelled Fab fragment of a monoclonal antibody in mice by systemic administration of lysine. Eur J Nucl Med 1994;21(7):663-665
97. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55(17):3825-3834
98. Behr TM, Becker WS, Sharkey RM, et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 1996;37(5):829-833
99. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25(2):201-212
100. Batuman V, Verroust PJ, Navar GL, et al. Myeloma light chains are ligands for cubilin (gp280). Am J Physiol 1998;275(2 Pt 2):F246-54
101. Klassen RB, Allen PL, Batuman V, et al. Light chains are a ligand for megalin. J Appl Physiol 2005;98(1):257-263
102. Williams PD, Hottendorf GH, Bennett DB. Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides. J Pharmacol Exp Ther 1986;237(3):919-925
103. Josepovitz C, Pastoriza-Munoz E, Timmerman D, et al. Inhibition of gentamicin uptake in rat renal cortex in vivo by aminoglycosides and organic polycations. J Pharmacol Exp Ther 1982;223(2):314-321
104. Malis CD, Racusen LC, Solez K, Whelton A. Nephrotoxicity of lysine and of a single dose of aminoglycoside in rats given lysine. J Lab Clin Med 1984;103(5):660-676
105. Ota Z, Makino H, Takaya Y. Molecular sieve in renal glomerular and tubular basement membranes as revealed by electron microscopy. Ren Physiol 1980;3(1-6):317-323
106. Nakaoka R, Tabata Y, Yamaoka T, Ikada Y. Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification. J Control Release 1997;46(3):253-261